Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).
Aged
Body Weight
/ drug effects
Diabetes Mellitus, Type 2
/ complications
Female
Glomerular Filtration Rate
/ drug effects
Glucagon-Like Peptides
/ analogs & derivatives
Humans
Hypoglycemic Agents
/ pharmacology
Immunoglobulin Fc Fragments
/ pharmacology
Male
Middle Aged
Recombinant Fusion Proteins
/ pharmacology
Renal Insufficiency, Chronic
/ complications
GLP-1
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
18
09
2018
revised:
30
01
2019
accepted:
12
02
2019
pubmed:
15
2
2019
medline:
30
5
2020
entrez:
15
2
2019
Statut:
ppublish
Résumé
In patients with type 2 dibetes and moderate-to-severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. As BW may affect muscle mass, creatinine-based eGFR can be altered independently of kidney function. Cystatin C-based eGFR is not affected by muscle mass. The objective of this post-hoc analysis was to determine whether the lesser eGFR decline with dulaglutide was related to BW loss. Baseline characteristics were similar between treatments ([mean ± SD] age, 64.6 ± 8.6 years; women, 48%; BW, 89.1 ± 17.7 kg; eGFR [CKD-EPI-cystatin C] 38 ± 14 mL/min/1.73m
Substances chimiques
Hypoglycemic Agents
0
Immunoglobulin Fc Fragments
0
Recombinant Fusion Proteins
0
Glucagon-Like Peptides
62340-29-8
dulaglutide
WTT295HSY5
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1493-1497Informations de copyright
© 2019 John Wiley & Sons Ltd.